Endovascular implant with an active coating

• US 20040073297A1
• Filed: 08/11/2003
• Published: 04/15/2004
• Est. Priority Date: 08/13/2002
• Status: Abandoned Application

• Current Assignee: Biotronik Mess-Und Therapiegeraete GmbH & Company Ingenieurbuero Berlin (Biotronik SE & Company KG)
• Original Assignee: Biotronik Mess und Therapiegeraete GmbH and Co (Biotronik SE & Company KG)
• Inventors: Diener, Tobias, Sternberg, Katrin, Rohde, Roland
• Application Number:
  US10/639,246
• Publication Number:
  US 20040073297A1
• Time in Patent Office: Days
• US Class Current: 623/1.46
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPARα-agonists, PPARδ-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists.

Claims

1. An endovascular implant, comprising:

an at least portion-wise active coating comprising a combination of PPAR-agonists and RXR-agonists as an active substance.

2. The implant of claim 1, wherein:

the active substance further comprises a fibrate from the group consisting of clofibrate, etofibrate, etofyllinclofibrate, bezafibrate, fenofibrate and gemfibrozil.

3. The implant of claim 1, wherein:

the active substance further comprises a glitazone from the group consisting of ciglitazone, pioglitazone, rosiglitazone and troglitazone.

4. The implant of claim 1, wherein:

the active substance further comprises bexarotene or phytanic acid.

5. The implant of claim 1, wherein:

the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

15. The implant of claim 2, wherein:

the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

16. The implant of claim 3, wherein:

the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

17. The implant of claim 4, wherein:

the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

6. An endovascular implant, comprising:

an at least portion-wise active coating comprising a PPARα

-agonist, a PPARδ

-agonist, or a combination thereof as an active substance.

7. The implant of claim 6, wherein:

the active substance further comprises a fibrate from the group consisting of clofibrate, etofibrate, etofyllinclofibrate, bezafibrate, fenofibrate and gemfibrozil.

8. The implant of claim 7, wherein:

the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

18. The implant of claim 7, wherein:

the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

9. An endovascular implant, comprising:

an at least portion-wise active coating comprising an RXR-agonist as an active substance.

10. The implant of claim 9, wherein:

the active substance further comprises bexarotene or phytanic acid.

11. The implant of claim 10, wherein:

the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

19. The implant of claim 9, wherein:

the active coating further a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.

12. A process for local treatment of stenosis or re-stenosis of a portion of a blood vessel, comprising the steps of:

providing an endovascular implant with an at least portion-wise active coating comprising a combination of a PPAR-agonist and a RXR-agonist as an active substance; and

placing the endovascular implant into the portion of the blood vessel.

13. A process for local treatment of stenosis or re-stenosis of a portion of a blood vessel, comprising the steps of:

providing an endovascular implant with an at least portion-wise active coating comprising a PPARα

-agonist, PPARδ

-agonists or a combination thereof as an active substance; and

placing the endovascular implant into the portion of the blood vessel.

14. A process for local treatment of stenosis or re-stenosis of a portion of a blood vessel, comprising the steps of:

providing an endovascular implant with an at least portion-wise active coating comprising an RXR-agonist as an active substance; and

placing the endovascular implant into the portion of the blood vessel.